Background. For several decades, it has been thought that the glomerular basement membrane (GBM) provides a charge-selective barrier for glomerular filtration. However, recent evidence has presented challenges to this concept: selective removal of heparan sulfate (HS) moieties that impart a negative charge to the GBM causes little if any increase in proteinuria. Removal of agrin, the major GBM HS-proteoglycan (HSPG), from the GBM causes a profound reduction in the glomerular anionic charge without changing the excretion of a negatively charged tracer. Perlecan is another HSPG present in the GBM, as well as in the mesangium and Bowman's capsule, that could potentially contribute to a charge barrier in the absence of agrin. Methods. Here we studied the nature of the glomerular filtration barrier to albumin in mice lacking the HS chains of perlecan either alone or in combination with podocytespecific loss of agrin. Results. The results show significant reductions in anionic sites within the GBM in perlecan-HS and in perlecan-HS/agrin double mutants. Podocyte and overall glomerular architecture were normal, and renal function was normal up to 15 months of age with no measurable proteinuria. Moreover, excretion of a negatively charged Ficoll tracer was unchanged as compared to control mice. Conclusions. These findings cast further doubt upon a critical role for the GBM in charge selectivity.
Introduction
The glomerular capillary wall serves as a semi-permeable filtration barrier. Classic experiments from the 1970s suggested the existence of a size-selective component based on the differential clearance of dextrans with radii between
Correspondence and offprint requests to: Jeffrey H. Miner, Renal Division 8126, 660 S. Euclid Ave., St Louis, MO 63110, USA. Tel: +1-314-362-8235; Fax: +1-314-362-8237; E-mail: minerj@wustl.edu 18 and 60 Å [1] . However, it was noted that proteins such as albumin possessed filtration characteristics that could not be wholly accounted for by their size, with fractional clearances lower than what would be predicted from studies of dextrans of equal size [2] [3] [4] [5] . This phenomenon was explained in part by conformational differences between the random coil of dextrans and the prolate ellipsoid of albumin [6] . Ficoll, a spherical polysaccharide more rigid than its dextran counterpart, also exhibited a fractional clearance less than would be expected based upon size alone [7, 8] .
The concept of charge selectivity arose from these early observations [9] . Electrostatic forces were thought to also account for the diminished clearance of albumin, which is a polar protein with an overall net charge between −12 and −18 at physiologic pH [6] . Furthermore, studies with differentially charged dextrans showed that, at a given molecular radius, neutral dextrans were filtered more freely than negatively charged dextran sulfate, but with a lower clearance than polycationic DEAE dextran [10] . Similar results were obtained with differentially charged variants of horseradish peroxidase [11] .
It was postulated that electrostatic repulsion at the glomerular filtration barrier accounted for these observations. The components of the glomerular capillary wall are known to possess an overall net negative charge, provided at anatomically distinct sites. Podocalyxin, a sialylated transmembrane protein, largely provides the anionic charge found within the glycocalyx of endothelial cells and podocytes [12] . In the latter, podocalyxin is thought to play a critical role in the maintenance of foot process architecture due in part to its extracellular charge but perhaps more so to its linkage to the actin cytoskeleton via ezrin [13, 14] . The glomerular basement membrane (GBM) likewise possesses a net negative charge, with sulfated glycosaminoglycan side chains of its constituent proteoglycans providing the majority of the anionic charge. Heparan sulfate (HS) proteoglycans (HSPGs) have been described along the lamina rara externa and to a lesser extent along the lamina rara interna [15] [16] [17] .
Three distinct HSPGs have been identified within the GBM: agrin, perlecan and collagen XVIII [18] . Agrin is produced primarily by the podocytes, and it is the predominant proteoglycan of adult GBM in all species studied [19] .
It exists as a core protein of 212 kDa with at least two HS side chains [20] . It is also present at nerve-muscle synapses where it plays an important developmental role, with Agrn knockout mice dying at birth due to paralysis caused by the absence of neuromuscular junctions [21] . Perlecan, in contrast, is produced primarily by glomerular endothelial cells and is present in the GBM during development. Later, perlecan is found predominantly in the mesangial matrix and Bowman's capsule, as is collagen XVIII [22, 23] . Perlecan's core protein of 467 kDa is linked to three HS glycosaminoglycan side chains via N-terminal domain I attachment sites [24, 25] . Homozygous perlecan-null (Hspg2−/−) mice die in utero or shortly after birth with disordered cartilage matrix and basement membrane disruption in regions of increased mechanical stress [26, 27] , but animals homozygous for an exon-specific mutation that removes the HS attachment sites (Hspg2 3/ 3 ) exhibit only mild extrarenal defects and are otherwise viable and fertile [28] .
Our prior work [29] examined mice with a podocytespecific knockout of agrin. These mice were developmentally normal, viable as adults and fertile. The glomerular filtration barrier was not compromised despite the absence of a major GBM component (agrin) and a significant reduction in the subepithelial GBM anionic charge. In addition, the fractional clearance of an anionic tracer was unchanged. These results suggest that GBM charge is not a major contributor to glomerular charge selectivity. The present study examines the potential role of perlecan's HS side chains by investigating whether their loss, either alone or in combination with podocyte-specific agrin deficiency, results in a change in glomerular charge selectivity.
Methods

Agrin and perlecan mutant mice
Mice denoted herein as agrin mutants possessed two nonfunctional Agrn alleles in podocytes. Mutants carried either two conditional 'floxed' Agrn alleles (Agrn fl/fl ) or one floxed and one null (Agrn del/fl ) allele in the presence of the 2.5 PCre transgene, which uses the human podocin (NPHS2) promoter to drive Cre expression specifically in podocytes [30] . The Agrn fl allele harbours loxP sites within introns 6 and 33, and the intervening genomic sequence is removed upon Cre-mediated recombination to generate a null allele [29] . In the Agrn del allele, the genomic sequence from within exon 6 to intron 33 is replaced by a PGK-neo cassette [21] .
Mice denoted as perlecan mutants possessed two copies of the mutated perlecan gene (Hspg2). The allele (Hspg2 3 ) contains a deletion of exon 3, removing the sites for HS attachment, as previously described [28] .
Agrin/perlecan double mutants were generated by intercrossing. Both Agrn and Hspg2 are on chromosome 4 and are separated by 8.6 centimorgans, which facilitated the production of double mutants once the targeted alleles became linked via meiotic recombination. Control mice had at least one wild-type allele for both Agrn and Hspg2 and/or lacked the 2.5 PCre transgene. All mice were studied on a mixed 129 × C57BL/6J × CBA/J background. Animal experiments were approved by the Washington University Animal Studies Committee.
Histology and immunostaining
Kidneys were formalin fixed and paraffin embedded prior to sectioning and staining with haematoxylin and eosin (H&E) or periodic acid-Schiff (PAS) reagent for light microscopy. Kidneys were also embedded in optimal cutting temperature compound (Sakura finetek, Torrance, CA, USA) and frozen in 2-methylbutane cooled in a dryice/ethanol bath. Unfixed cryosections were immunostained after being blocked with 1.5% goat serum in PBS. For agrin staining, the rabbit anti-mouse agrin LG (COOHterminus) antibody (T. Sasaki, Oregon Health & Sciences University, Portland, OR, USA) was used at a 1:25 000 dilution [19] . For HS detection, the sections were fixed for 10 min in acetone fixing at 4
• C and blocked using the Mouse-on-Mouse kit (Vector Laboratories, Burlingame, CA, USA) prior to staining with the antibody JM403 (Seikagaku Corporation, Tokyo, Japan) at a 1:100 dilution [31] . The secondary fluorophore-labelled antibodies were Cy3-conjugated goat anti-rabbit IgG (1:500) for agrin and FITC-conjugated goat anti-mouse IgM (1:100) for HS.
Electron microscopy and polyethyleneimine labelling
For routine electron microscopy, kidney cortices were immersion fixed in 2% paraformaldehyde and 2% glutaraldehyde in a 0.1 M sodium cacodylate buffer, pH 7.2. Tissue was then post-fixed in 1% OsO 4 and serially dehydrated prior to embedding in Polybed (Polysciences, Warrington, PA, USA). Counterstaining was performed with uranyl acetate and lead citrate. Thin sections were examined with a CX-100 electron microscope (JEOL, Tokyo, Japan). The GBM thickness was measured along 15 evenly spaced points within each photograph. Comparisons were made after the thickest and thinnest measurements in each photograph were excluded.
For polyethyleneimine (PEI) labelling, a minced kidney cortex was incubated in 0.5% PEI (1.8 kDa; Sigma, St Louis, MO, USA) in 0.9% NaCl, pH 7.3 for 30 min. The specimens were then washed in a 0.1 M sodium cacodylate buffer and incubated in 2% phosphotungstic acid and 2.5% glutaraldehyde in a 0.1 M sodium cacodylate buffer for 1 h. Tissue was then post-fixed and embedded as above. Glomerular capillary loops were photographed at 14 000× magnification, and the number of PEI aggregates per micrometre was counted along each aspect of the GBM (subepithelial and subendothelial). Several litters of adult mice between the ages of 9 and 15 months were analysed using this technique, with totals of two controls, one agrin mutant, four perlecan mutants and three agrin/perlecan double mutants.
Clinical chemistry and Ficoll clearance studies
Urinary protein concentrations were measured using Biuret reactions, and creatinine concentrations were measured using Jaffe reactions, each on a Cobas Mira Plus analyser (Roche Diagnostics, Indianapolis, IN, USA). Levels of total serum protein and blood urea nitrogen were also analysed. For Ficoll clearance studies, the mice underwent tail injection with a bolus of FITC-labelled carboxymethyl Ficoll-70 in 0.9% NaCl (TdB Consultancy, Uppsala, Sweden) at a dose of 250 µg/g of body weight. The mice were housed for 24 h in metabolic cages (Hatteras Instruments, Cary, NC, USA), and their urine samples were collected and assayed. The concentration of tracer present in the urine was determined on a QuantaMaster fluorimeter (Photon Technology International, Lawrenceville, NJ, USA) using an excitation wavelength of 488 nm and an emission wavelength of 529 nm. The experimental samples were compared with standards after dilution in 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.5. Clearance of the tracer was expressed as the percentage of the total amount injected that was excreted in 24 h.
Statistical analyses
The two-sample t-test was used to analyse the PEI, urinalysis and serum data, as well as the Ficoll fractional clearances. Differences were considered to be significant at P < 0.05.
Results
Disruption of GBM-HSPGs alone or in combination does not disrupt renal function
All mutants displayed normal development and survival into adulthood through at least 15 months of age. Testing for underlying renal dysfunction by analysing blood urea nitrogen levels demonstrated no significant differences between the mutants (perlecan mutants or agrin/perlecan double mutants) and controls ( Table 1 ). The wild-type average blood urea nitrogen of 19.1 ± 5.6 mg/dL did not differ statistically from that of the perlecan mutant group (26.2 ± 1.8 mg/ dL, P = 0.07) or the double-mutant group (21.9 ± 9.3 mg/ dL, P = 0.20). Likewise, there was no statistical difference between the serum protein measurements ( Table 1) . The wild-type group had an average serum protein level of 5.04 ± 0.6 g/dL, which was not significantly different from the perlecan mutant group (4.26 ± 1.3 g/dL, P = 0.21) or the double-mutant group (4.54 ± 1.6 g/dL, P = 0.45). Urine samples from all groups were analysed for protein levels and standardized to creatinine concentration. The urinary protein-to-creatinine ratios (mg/mg) demonstrated no significant differences among the groups ( Table 1) . The double-mutant group (20.9 ± 9.1) showed no difference as compared to the control group (20.8 ± 12.5, P = 0.98). Furthermore, no statistical difference was observed when the double-mutant group was compared to the perlecan mutant group (31.46 ± 16.7, P = 0.19).
Immunofluorescence reveals selective loss of agrin in the GBM of agrin and double mutants
As we previously showed, mice lacking a functional agrin allele in podocytes (Agrn fl/fl ; 2.5 PCre and Agrn del/fl ; 2.5 PCre mice) demonstrated a dramatic reduction in GBM agrin ( Figure 1B and D) . Whether agrin was eliminated alone or in combination with perlecan-HS, the agrin mutants showed glomerular agrin deposition that was confined primarily to the mesangial matrix. In contrast, the control and perlecan mutant groups showed bright, linear staining for agrin along the GBM ( Figure 1A and C) .
Differential reduction of glomerular heparan sulfate in perlecan, agrin and double mutants
We used the anti-HS antibody JM403 to label HS in adult kidneys. The glomeruli of the control mice revealed staining in the mesangium as well as linearly along the GBM (Figure 2A) . The selective elimination of podocyte agrin synthesis led to an absence of HS staining in the GBM, but mesangial deposition was preserved ( Figure 2B ). The reverse was found in the perlecan mutants: mesangial staining was diminished, whereas the GBM maintained its distinctive linear staining pattern ( Figure 2C ). The double mutants showed an overall decrease in staining for HS, although this effect was variable throughout the kidney ( Figure 2D ). These staining patterns suggest that while there may be some overlap, agrin was primarily localized to the GBM, whereas perlecan was present mostly in the mesangium.
Light and electron microscopy reveals no renal structural defects in mutants
When compared to wild-type controls, no histological abnormalities were noted in the kidneys in the singleor double-mutant animals. Figure 3 shows the normal glomerular architecture, with open and intact capillary loops, no obvious GBM thickening and no mesangial expansion. Likewise, the tubular architecture showed no differences between the wild-type and mutant mice by both H&E and PAS staining (Figure 4) . Glomerular ultrastructure in mutants was indistinguishable from the controls ( Figure 5 ). All genotypes demonstrated the maintenance of organized podocyte foot process architecture. Irregularities of the GBM were present in all groups in comparable numbers, including the control kidneys and likely were plane-of-section artefacts. GBM thicknesses were measured and are shown in Figure 6 . There were no statistically significant differences among any of the groups.
Polyethyleneimine labelling demonstrates significant GBM charge alterations
PEI labelling was used to visualize anionic sites along the GBM (Figure 7) . Quantitation of the number of subepithelial anionic sites per micrometre revealed no difference between the perlecan mutant and the wild-type littermate control (11.21 ± 1.0 versus 11.15 ± 1.2, P = 0.89). However, agrin mutants showed a significant reduction in charged sites compared with littermate controls (4.34 ± 0.3 versus 11.15 ± 1.2, P < 0.001) and with the perlecan-only mutants (4.34 ± 0.3 versus 11.21 ± 1.0, P < 0.001). A similar reduction was also found in the agrin/perlecan double mutants as compared to littermate controls (4.73 ± 2.3 versus 11.15 ± 1.2, P < 0.001) and to the perlecan-only mutants (4.73 ± 2.3 versus 11.21 ± 1.0, P < 0.001). There was no difference between the agrin-only mutant group and the double mutants (4.34 ± 0.3 versus 4.73 ± 2.3, P = 0.72). Of note, the double-mutant kidneys showed stretches of GBM with PEI staining comparable to the control group; these accounted for 20% of the length of the GBM that was photographed and measured. These could represent either agrin-positive segments stemming from inefficient Cre activity in a subset of podocytes or upregulated deposition of an alternative anionic protein, such as collagen XVIII. These regions were included in the calculations, demonstrating statistical significance nonetheless.
Subendothelial PEI labelling differed between some groups. Although no difference was found between agrinonly mutants and littermate controls (4.80 ± 0.5 versus 5.03 ± 0.7, P = 0.53), the perlecan-only mutants demonstrated a reduction in anionic sites as compared both to littermate controls (3.83 ± 0.8 versus 5.03 ± 0.7, P < 0.001) and to the agrin-only mutant group (3.83 ± 0.8 versus 4.80 ± 0.5, P = 0.02). Likewise, a similar reduction was found between the agrin/perlecan mutants as compared to the littermate controls (3.93 ± 0.8 versus 5.03 ± 0.7, P = 0.002) as well as the agrin-only mutants (3.93 ± 0.8 versus 4.80 ± 0.5, P = 0.03). There was no difference between the perlecan-only mutant group and the double mutants (3.83 ± 0.8 versus 3.93 ± 0.8, P = 0.70).
Ficoll clearance is unaffected in double mutants
Next we investigated whether the reduction in GBM anionic sites increased the rate of clearance of a negatively charged tracer, which would be expected if these sites contribute to the charge barrier. Urinary excretion of intravenously injected, fluorescently labelled carboxymethy-Ficoll-70 was measured, and the overall fractional clearance was determined and expressed as the percentage of the total amount injected that was excreted over a 24-h period. These data are shown in Table 2 . There were no statistically significant differences among the groups. The control group averaged a Ficoll clearance of 24.10% ± 8.3%, and this did not differ from the perlecan group (26.25% ± 17.7%, P = 0.78) or the double-mutant group (27.36% ± 5.9%, P = 0.59).
Discussion
This study tested the hypothesis that the observed charge selectivity of the glomerular filter is provided by the intrinsic negative charge of the GBM. However, our results challenge this theory by showing that removal of components known to provide the GBM with its negative charge did not lead to a measurable difference in the fractional clearance of a negatively charged tracer. These findings are in agreement with and extend our earlier work showing that the selective loss of podocyte-derived agrin had no effect on glomerular filtration despite the significant loss of ∼50% of the anionic sites along the GBM [29] . Here we demonstrated a similar reduction in the subepithelial charge density when agrin was eliminated along with perlecan-HS (double mutants).
Perlecan, which is present in the adult GBM, albeit to a much lesser degree than agrin, was shown to contribute to the overall negative charge. The mice lacking the HS attachment sites on perlecan demonstrated a statistically significant reduction in anionic sites along the GBM, though only along the subendothelial aspect. This was not unexpected, given that perlecan is produced primarily by the endothelial cells. The immunofluorescent staining for HS supports this pattern of expression, with a primarily mesangial loss in perlecan mutants, but preserved linear staining in the GBM. However, as with the Agrn mutant mice, disruption in this intrinsic charge did not result in any measurable difference in the fractional clearance of polyanionic Ficoll.
To show that a subtle compensatory upregulation of either agrin or perlecan expression in the absence of the other did not account for the lack of alterations in the glomerular barrier, we eliminated both components. These double mutants, like their agrin-only and perlecan-only mutant counterparts, displayed no observable histologic or ultrastructural abnormalities in glomeruli. Also, while they demonstrated diminished staining for HS and a decrease in subepithelial and subendothelial anionic sites, they showed no difference from control mice in the fractional clearance of negatively charged Ficoll.
The evaluation of both urine and serum samples showed no defects in kidney function. Urinary protein excretion, when standardized to creatinine, showed no evidence of proteinuria in any of the groups (control, perlecan-HS mutant and agrin/perlecan-HS double mutant). Also, Fig. 7 . Disruption of anionic sites in the GBM are manifested as a reduction in PEI labelling. In control mice, the punctuate PEI labelling is distributed in a semi-regular pattern along the subepithelial and subendothelial laminae rarae (A). Agrin mutants (B) show a reduction in the subepithelial labelling only, whereas perlecan mutants (C) show a decrease in the subendothelial layer only. Double mutants (D) show diminished labelling along both the subepithelial and subendothelial aspects. Quantitative analyses (E and F) reveal a significant reduction in subepithelial labelling in agrin mutants and double mutants when compared to littermate controls and perlecan mutants (P < 0.001). A significant reduction in subendothelial labelling was found in perlecan mutants and double mutants when compared to littermate controls and agrin mutants (P < 0.03). Magnification 14 000×; scale bar, 1 µm. measurements of blood urea nitrogen levels as well as protein concentrations revealed no significant differences. The mice used in this study were at least 9 months old, and through at least 15 months of age they demonstrated no survival disadvantages. Taken together, these results suggest that an electrostatic charge barrier to negatively charged compounds is not provided by the proteoglycan components of the GBM. Other work has shown that an isolated GBM loses much of its charge-selective properties [32] . Moreover, HS, while comprising the majority of the anionic charge within the GBM, makes up only 1% of the overall dry weight of the rat GBM matrix [33] . Type IV collagen comprises a majority of the GBM scaffolding and is known to possess carbohydrate side-chain moieties, including negatively charged sialic acid residues [34] . Thus, a contribution of type IV collagen to the GBM's negative charge, which should be unaffected by the selective knockout of agrin and perlecan-HS, cannot be fully excluded.
More recent evidence also agrees with our findings. In one study, overexpression of heparanase similarly resulted in neither alteration of glomerular architecture nor decline in renal function, despite a small but statistically significant increase in albuminuria [35] . In another study, podocytespecific knockout of Ext1, whose gene product is required for HS synthesis, did not lead to significant albuminuria [36] .
The question regarding the source and location of the charge barrier, if such a barrier exists, remains unanswered. Focus has shifted from the extracellular matrix towards the cellular constituents of the glomerular filtration barrier. Such candidates would include the negatively charged glycocalyx of both endothelial cells and podocytes. On the capillary side, endothelial cells have been noted to desulfate exogenously administered polysaccharides [37, 38] . Such modification and removal of negative charges may result in an effective decrease in their concentration at the filtration interface, and this, as well as cellular uptake time, may thus reduce their rate of passage across the barrier [39] . In podocytes, loss of podocalyxin has been shown to lead to perinatal lethality with effacement of the foot processes [13] . Distortion of this delicate architecture has made it difficult to distinguish the specific effect of the loss of this negatively charged compound, although it is reasonable to suggest that it is the charge itself that allows for the maintenance of normal podocyte structure and function. Alternatively, there is evidence that podocalyxin may contribute to organizing the podocyte cytoskeleton independent of its anionic charge [40] .
